Kenalog in Orabase
Kenalog in Orabase Brand names, Kenalog in Orabase Analogs
- Adcortyl
- Aristocort
- Aristocort A
- Aristocort Tablets
- Aristogel
- Aristospan
- Azmacort
- Celeste
- Cinolone
- Cinolone-T
- Delphicort
- Fluoxiprednisolone
- Fluoxyprednisolone
- Flutex
- Kenacort
- Kenacort-A
- Kenacort-Ag
- Kenalog
- Kenalog in Orabase
- Kenalog-10
- Kenalog-40
- Kenalog-H
- Ledercort
- Nasacort
- Nasacort Aq
- Nasacort Hfa
- Omcilon
- Omicilon
- Oracort
- Oralone
- Orion
- Polcortolon
- Rodinolone
- Sk-Triamcinolone
- Tiamcinolonum [Inn-Latin]
- Tri-Nasal
- Triacet
- Triacort
- Triam-Tablinen
- Triamcet
- Triamcinalone
- Triamcinlon
- Triamcinolon
- Triamcinolona [Inn-Spanish]
- Triamcinolone Acetonide
- Triamcinolone Acetonide in Absorbase
- Triamcinolone Diacetate
- Triamcinolone [Usan:Ban:Inn:Jan]
- Triamcinolonum [Inn]
- Triatex
- Tricortale
- Triderm
- Trymex
- Vetalog
- Volon
Kenalog in Orabase Brand Names Mixture
- Aristoform R Crm 0.1% (Clioquinol + Triamcinolone Acetonide)
- Derma-4 Ont (Neomycin Sulfate + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
- Kenacomb Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
- Kenacomb Mild Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
- Kenacomb Mild Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
- Kenacomb Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
- Kenacomb Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Mecomb Crm 0.1% (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Oribiotic Ointment (Bacitracin + Lidocaine + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Panolog Cream (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
- Panolog Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
- Ratio-Triacomb Regular Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Solvaderm Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
- Theraderm Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Viaderm Kc Crm (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
- Viaderm Kc Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
Kenalog in Orabase Chemical_Formula
Kenalog in Orabase RX_link
Kenalog in Orabase fda sheet
Kenalog in Orabase msds (material safety sheet)
Kenalog in Orabase Synthesis Reference
Kenalog in Orabase Molecular Weight
Kenalog in Orabase Melting Point
Kenalog in Orabase H2O Solubility
Kenalog in Orabase State
Kenalog in Orabase LogP
Kenalog in Orabase Dosage Forms
Kenalog in Orabase Indication
Kenalog in Orabase Pharmacology
Kenalog in Orabase Absorption
Kenalog in Orabase side effects and Toxicity
Kenalog in Orabase Patient Information
Patients being treated with Azmacort Inhalation Aerosol should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a complete disclosure of all possible adverse or intended effects.
Patients should use Azmacort Inhalation Aerosol at regular intervals as directed. Results of clinical trials indicate that significant improvement in asthma may occur by 1 week, but maximum benefit may not be achieved for 2 weeks or more. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens.
In clinical studies and post-marketing experience with Azmacort Inhalation Aerosol, local infections of the oropharynx with Candida albicans have occurred. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while remaining on treatment with Azmacort Inhalation Aerosol. However, at times therapy with Azmacort Inhalation Aerosol may need to be interrupted.
Patients should be instructed to track their use of Azmacort Inhalation Aerosol and to dispose of the canister after 240 actuations since reliable dose delivery cannot be assured after 240 doses.
Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and if exposed, to obtain medical advice.
